Recruiting psychedelic and ketamine trials in Europe, with entry criteria
18 / 73 recruiting studies with structured, adjudicated entry criteria / listed European sites across 17 countries
Registries publish recruiting trials in regulatory language; this dataset restructures them into the three fields that decide a referral or an application: indication, age window, and whether documented failed treatments are required, plus the per-country site list. Every study was adjudicated by hand from its CTIS or ClinicalTrials.gov record; registry status lags reality, so current enrolment is always a question for the site.
Recruiting studies and their hard entry criteria (full dataset; also available as CSV)
| Study | Condition | Age | Failed treatments required | Countries with sites |
|---|---|---|---|---|
| LSD for cluster headache | other | 25 to 75 | no | CH |
| LSD for alcohol use disorder | addiction | 25+ | no | CH |
| LSD for chronic cluster headache | other | 16 to 75 | no | NL |
| BPL-003 (5-MeO-DMT) for treatment-resistant depression | trd | 18 to 75 | yes | UK |
| LSD in palliative care | other | 22+ | no | CH |
| Intensified pharmacological treatment after first-line failure (depression) | trd | 18 to 65 | yes | IT, AT |
| Single-dose psilocybin for cancer-related major depression | depression | 20 to 80 | no | SE |
| Psilocybin for fibromyalgia pain | other | 18 to 65 | no | NL |
| Psilocybin for hospitalized treatment-resistant depression | trd | 18+ | yes | BE |
| Psilocybin for psychological distress in palliative patients | other | 18+ | no | CZ, DK, NL, PT |
| CYB003 (psilocin analog) adjunct for major depressive disorder | depression | 18 to 85 | yes | CZ, DE, GR, IE, PL, UK |
| Psychedelic-augmented imagery intervention, young people with self-harm | other | 16 to 25 | no | UK |
| DMT (masked with propofol) for major depressive disorder | depression | 21+ | no | CH |
| Esketamine metabolic profiling in major depressive disorder | depression | 18 to 70 | no | HR |
| Psilocybin with psychological support in anorexia nervosa (16-35) | other | 16 to 35 | no | SE |
| Esketamine for major depressive disorder in adolescents (12-17) | depression | 12 to 17 | no | HU |
| Psilocybin and anhedonia in major depressive disorder | depression | 18 to 55 | no | AT |
| Psilocybin for relapse prevention in alcohol use disorder with depressive symptoms | addiction | 18+ | no | FR |
Methodology
- One row per recruiting interventional study in our trial layer; criteria are transcribed (adjudicated) by hand from the official registry record (CTIS or ClinicalTrials.gov), each linked from the study's entry in our directory.
- 'Failed treatments required' flags protocols whose inclusion criteria demand documented unsuccessful prior treatment; the exact wording differs per protocol and is on the study record.
- Site lists are the European sites named in the registry record, matched to our provider catalog where a site is also a listed provider.
- Registry status lags enrolment reality in both directions; the site contact, not this table, is the source of truth for whether screening is open this week.
- Patients can check themselves against these criteria in about two minutes via our eligibility check (trial route); the study team always makes the final call at screening.
Sources
- CTIS, the EU Clinical Trials Information System
- ClinicalTrials.gov
- PsyAccess trial checker (pre-screening route)
- How trials work: phases, placebo, consent
How to cite
PsyAccess (2026). Recruiting psychedelic and ketamine trials in Europe, with entry criteria. https://psyaccess.health/data/open-trials-europe/ (updated 2026-10-06). Licensed CC BY 4.0.
Embed this figure
<p>18 / 73 recruiting studies with structured, adjudicated entry criteria / listed European sites across 17 countries. Source: <a href="https://psyaccess.health/data/open-trials-europe/">PsyAccess: Recruiting psychedelic and ketamine trials in Europe, with entry criteria</a> (CC BY 4.0, updated 2026-10-06).</p>